MedTrace Logo

Telomere Biology in Early Adenocarcinoma of the Lung

NCT02239432 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2014-09-12

No results posted yet for this study

Summary

Early adenocarcinoma of the lung has an excellent five-year survival after resection. However, its clinical and radiologic presentation is highly variable. Traditional means for preoperative diagnosis such as Positron Emission Tomography (PET-CT) and trans-thoracic needle biopsy demonstrate unacceptable false positive and negative rates.

Telomere biology is activated aberrantly is most lung cancers but has not been studied in early stages to the best of our knowledge.

The objective of this study is to evaluate telomere length and activity with suspected early stage adenocarcinoma of the lung.

Conditions

  • Adenocarcinoma of the Lung
  • Adenocarcinoma, Bronchiolo-Alveolar

Sponsors & Collaborators

  • Meir Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-09-30
Completion
2017-09-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02239432 on ClinicalTrials.gov